Skip to main content
. 2019 Oct 15;49(12):1083–1091. doi: 10.1093/jjco/hyz135

Figure 2.

Figure 2.

(A) Overall survival in Japanese patients (ITT) and (B) PD-L1–positive patients. Atezo, atezolizumab.